Drug profile · INN
dapagliflozin, saxagliptin monohydrate
DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE
dapagliflozin, saxagliptin monohydrate (DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.
Drug details — dapagliflozin, saxagliptin monohydrate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
dapagliflozin, saxagliptin monohydrate (DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.
Key facts
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Frequently asked questions
What is dapagliflozin, saxagliptin monohydrate?
dapagliflozin, saxagliptin monohydrate (DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for dapagliflozin, saxagliptin monohydrate?
DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE is a marketed brand name for dapagliflozin, saxagliptin monohydrate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of dapagliflozin, saxagliptin monohydrate?
dapagliflozin, saxagliptin monohydrate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.